DRUG CHOICES BASED ON MANAGED CARE STUDIES IS A KEY ISSUE FOR FDA-AGENCY's ADAMS; QUESTIONS RAISED ON FULL DISCLOSURE IN INTERACTIVE MEDIA
Executive Summary
The possibility of managed care organizations making drug treatment decisions based on their own studies "is going to be one of the main policy questions [FDA] is going to have to answer in the next few years," FDA Policy Development and Coordination Staff Director David Adams told the Regulatory Affairs Professionals Society March 1 in Chicago.